MA46652A - Polythérapie pour l'inhibition de c3 - Google Patents

Polythérapie pour l'inhibition de c3

Info

Publication number
MA46652A
MA46652A MA046652A MA46652A MA46652A MA 46652 A MA46652 A MA 46652A MA 046652 A MA046652 A MA 046652A MA 46652 A MA46652 A MA 46652A MA 46652 A MA46652 A MA 46652A
Authority
MA
Morocco
Prior art keywords
polytherapy
inhibition
Prior art date
Application number
MA046652A
Other languages
English (en)
Inventor
Cedric Francois
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of MA46652A publication Critical patent/MA46652A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
MA046652A 2016-10-17 2017-10-16 Polythérapie pour l'inhibition de c3 MA46652A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662409357P 2016-10-17 2016-10-17

Publications (1)

Publication Number Publication Date
MA46652A true MA46652A (fr) 2019-08-21

Family

ID=62019501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046652A MA46652A (fr) 2016-10-17 2017-10-16 Polythérapie pour l'inhibition de c3

Country Status (12)

Country Link
US (2) US11338013B2 (fr)
EP (1) EP3526328A4 (fr)
JP (2) JP2020500157A (fr)
CN (2) CN118217402A (fr)
AU (1) AU2017346486B2 (fr)
BR (1) BR112019007613A2 (fr)
CA (1) CA3040917A1 (fr)
IL (1) IL266012B2 (fr)
MA (1) MA46652A (fr)
MX (1) MX2019004500A (fr)
RU (1) RU2019113301A (fr)
WO (1) WO2018075373A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2973883A1 (fr) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methodes de traitement d'un sujet atteint d'une deficience en phosphatase alcaline
ES2974107T3 (es) 2015-10-07 2024-06-25 Apellis Pharmaceuticals Inc Regímenes de dosificación
WO2018075373A1 (fr) 2016-10-17 2018-04-26 Apellis Pharmaceuticals, Inc. Polythérapie pour l'inhibition de c3
WO2018085208A1 (fr) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Procédés d'inhibition de virus à l'aide de compositions ciblant l'interaction tsg101-ubiquitine
JP2020516607A (ja) * 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
WO2019089922A1 (fr) * 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c3 et leurs procédés d'utilisation
EP3773684A1 (fr) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CA3160576A1 (fr) * 2019-12-06 2021-06-10 Sirnaomics, Inc. Vehicule d'amarrage de peptides pour l'administration ciblee d'acides nucleiques
JP2023514570A (ja) * 2020-02-14 2023-04-06 アペリス・ファーマシューティカルズ・インコーポレイテッド 補体阻害のためのｒｎａ
JP2024515344A (ja) * 2021-04-20 2024-04-09 アストラゼネカ アイルランド リミテッド 補体成分３の発現を阻害するための組成物及び方法
WO2022251484A1 (fr) * 2021-05-26 2022-12-01 Apellis Pharmaceuticals, Inc. Traitement de troubles à médiation par le complément
CN118434764A (zh) 2021-12-22 2024-08-02 Cdr生物科技股份有限公司 抗c3抗体及其抗原结合片段及其用于治疗眼疾病的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888323B2 (en) 2005-11-28 2011-02-15 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
NZ569368A (en) 2005-12-22 2011-11-25 Exegenics Inc D B A Opko Health Inc siRNA compositions and methods for regulating the C3 protein in the complement system
WO2009121065A2 (fr) * 2008-03-28 2009-10-01 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
MX356528B (es) * 2011-05-11 2018-06-01 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos.
ES2879430T3 (es) * 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014078734A2 (fr) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Analogues de la compstatine réactifs aux cellules, à longue durée d'action ou ciblés et compositions et méthodes associées
WO2014152391A1 (fr) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Analogues de compstatine pénétrant dans les cellules et leurs utilisations
WO2015089368A2 (fr) * 2013-12-12 2015-06-18 Alnylam Pharmaceuticals, Inc. Composition d'arni d'élément de complément et procédés pour les utiliser
WO2018075373A1 (fr) 2016-10-17 2018-04-26 Apellis Pharmaceuticals, Inc. Polythérapie pour l'inhibition de c3
WO2019089922A1 (fr) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant du complément c3 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
BR112019007613A2 (pt) 2019-07-02
EP3526328A1 (fr) 2019-08-21
EP3526328A4 (fr) 2020-05-27
AU2017346486A1 (en) 2019-05-23
IL266012B2 (en) 2024-09-01
RU2019113301A (ru) 2020-11-17
CN110249053A (zh) 2019-09-17
US20200282012A1 (en) 2020-09-10
IL266012B1 (en) 2024-05-01
US11338013B2 (en) 2022-05-24
IL266012A (en) 2019-06-30
RU2019113301A3 (fr) 2021-02-20
WO2018075373A1 (fr) 2018-04-26
CA3040917A1 (fr) 2018-04-26
JP2020500157A (ja) 2020-01-09
CN118217402A (zh) 2024-06-21
MX2019004500A (es) 2019-08-21
US20230009757A1 (en) 2023-01-12
JP2022188048A (ja) 2022-12-20
AU2017346486B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA53402A (fr) Immunomodulateurs pour l'imagerie tep
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA47420A (fr) Composés inhibiteurs d'oga
FR3021862B1 (fr) Kit d'operation pour mise en place de valve aortique
MA42999A (fr) Polythérapie pour le traitement de malignités
MA50533A (fr) Imipridones pour gliomes
MA49006A (fr) Inhibiteurs d'ip6k
MA41116A (fr) Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA39500A (fr) Compositions à base d'extraits de plantes pour l'inhibition de la 5-alpha-réductase
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
MA52934A (fr) Composés inhibiteurs de l'oga
FR3037614B1 (fr) Drain pour carter d'echappement de turbomachine
MA46898A (fr) Compositions pour la conservation d'organes
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
FR3039423B1 (fr) Materiau organosilicique pour la depollution de l'eau
FR3018897B3 (fr) Structure lineaire encastrable pour l'illumination
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
FR3033489B3 (fr) Guide pour le positionnement d'attaches orthodontiques
IT201700035964A1 (it) “divisorio per boiserie”
FR3040122B1 (fr) Casier formant nasse pour des mollusques